ArticleJournal of clinical hypertension (Greenwich, Conn.)2026
First Comparative Evaluation of TyG-ABSI Versus Traditional TyG-Related Indices for Cardiovascular Disease and Mortality Prediction in Hypertensive Patients: TyG-ABSI Versus Traditional TyG-Related Indices.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of long-term exposure to green space with cardiovascular health and the mediating role of triglyceride-glucose in dex in middle-aged and older Chinese adults: a nationwide cohort study.Journal of geriatric cardiology : JGC · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hypertension contributes substantially to the global burden of cardiovascular disease (CVD) and mortality. TyG-ABSI is a novel composite marker integrating insulin resistance and central obesity, both closely related to hypertensive pathophysiology. However, its predictive value in hypertensive populations remains unclear. This study investigated the association between TyG-ABSI and CVD and mortality among hypertensive adults and compared its predictive ability with traditional TyG-related indices. Data were obtained from the NHANES cycles from 2003 to 2018, including 7,775 participants with hypertension (mean age 56.68 ± 0.26 years; 50.42% male). Weighted Cox proportional hazards models and logistic regression were used to analyze associations with mortality outcomes and CVD, respectively. Kaplan-Meier curves and restricted cubic spline analyses were also conducted. Model performance was evaluated using ROC curves, continuous NRI, and IDI, with subgroup and sensitivity analyses assessing robustness. TyG-ABSI was significantly associated with increased risks of CVD, all-cause mortality, and cardiovascular mortality. Each 1-unit increase in TyG-ABSI was linked to a 38% higher risk of CVD (OR 1.38, 95% CI: 1.15-1.67), 84% higher all-cause mortality (HR 1.84, 95% CI: 1.51-2.24), and 83% higher cardiovascular mortality (HR 1.83, 95% CI: 1.37-2.45). Dose-response relationships were observed in tertile analyses and RCS models. Compared with traditional TyG-related indices, TyG-ABSI showed better predictive performance with higher AUC and significant improvements in NRI and IDI. These findings suggest that TyG-ABSI may serve as an effective tool for risk stratification in hypertensive patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.